# Phase II Dose-ranging Study of APD421 in PONV

> **NCT01510704** · PHASE2 · COMPLETED · sponsor: **Acacia Pharma Ltd** · enrollment: 215 (actual)

## Conditions studied

- Postoperative Nausea and Vomiting

## Interventions

- **DRUG:** APD421
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01510704
- **Lead sponsor:** Acacia Pharma Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 215 (ACTUAL)
- **Last updated:** 2019-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01510704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01510704, "Phase II Dose-ranging Study of APD421 in PONV". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01510704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*